Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market

Published by: GBI Research

Published: Jun. 1, 2011 - 177 Pages


Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Opioids Market to 2017: Introduction
2.1 GBI Research Report Guidance
3 Opioids Market: Market Overview
3.1 Introduction
3.2 Opioids: A Classification
3.2.1 Branded Generics Play a Major Role
3.2.2 Novel Drug Delivery Techniques Push Opioid Usage
3.3 Adverse Effects Associated With Opioids Restrain Its Prescription
3.4 REMS
3.4.1 What are REMS?
3.4.2 Implications of REMS
3.4.3 REMS for Opioids
3.5 Revenue
3.6 Major Marketed Opioids
3.6.1 Oxycontin
3.6.2 Embeda
3.6.3 Exalgo
3.6.4 Onsolis
3.6.5 Avinza
3.6.6 Duragesic
3.6.7 Kadian
3.6.8 Opana ER
3.6.9 Vicodin CR
3.6.10 Dolophine
3.6.11 MS Contin
3.6.12 Oramorph
3.7 FDA Regulations Regarding Opioids
3.7.1 FDA Regulations on Opioid Combinations with Acetaminophen
3.7.2 Darvocet, Darvon (Propoxyphene) Withdrawn From the Market
3.8 Annual Cost of Therapy
3.9 Treatment Usage Patterns
3.9.1 Diseased Population
3.9.2 Treatment Seeking Population
3.9.3 Diagnosed Population
3.9.4 Prescription Population
3.10 Drivers and Restraints of the Opioids Market
3.10.1 Drivers
3.10.2 Restraints
4 Opioids Market: Therapeutic Landscape
4.1 Opioids Market for Fibromyalgia
4.1.1 Introduction
4.1.2 Revenue and Forecasts
4.1.3 Annual Cost of Therapy
4.1.4 Treatment Usage Patterns
4.1.5 Geographical Segmentation
4.2 Drivers and Restraints for the Opioids Market for Fibromyalgia
4.2.1 Drivers
4.2.2 Restraints
4.3 Opioids for Neuropathic Pain
4.3.1 Introduction
4.3.2 Revenue and Forecasts
4.3.3 Annual Cost of Therapy
4.3.4 Treatment Usage Patterns
4.3.5 Geographical Segmentation
4.4 Drivers and Restraints for the Opioids Market for Neuropathic Pain
4.4.1 Drivers
4.4.2 Restraints
4.5 Opioids Market for Cancer Pain
4.5.1 Introduction
4.5.2 Revenue and Forecasts
4.5.3 Annual Cost of Therapy
4.5.4 Treatment Usage Patterns
4.5.5 Geographical Segmentation
4.5.6 Drivers and Restraints for the Opioids Market for Cancer Pain
4.5.7 Drivers
4.5.8 Restraints
4.6 Opioids Market for Osteoarthritis Pain
4.6.1 Introduction
4.6.2 Revenue and Forecasts
4.6.3 Annual Cost of Therapy
4.6.4 Treatment Usage Patterns
4.6.5 Geographical Segmentation
4.6.6 Drivers and Restraints for the Opioids Market for Osteoarthritis Pain
4.6.7 Drivers
4.6.8 Restraints
4.7 Opioids Market for Rheumatoid Arthritis Pain
4.7.1 Introduction
4.7.2 Revenue and Forecasts
4.7.3 Annual Cost of Therapy
4.7.4 Treatment Usage Patterns
4.7.5 Geographical Segmentation
4.7.6 Drivers and Restraints for Opioids Market for Rheumatoid Arthritis Pain
4.7.7 Drivers
4.7.8 Restrains
4.8 Opioids Market for Low Back Pain
4.8.1 Introduction
4.8.2 Revenue and Forecasts
4.8.3 Annual Cost of Therapy
4.8.4 Treatment Usage Patterns
4.8.5 Geographical Segmentation
4.8.6 Drivers and Restraints for the Opioids Market for Low Back Pain
4.8.7 Drivers
4.8.8 Restraints
4.9 Opioids Market for Post-operative Pain
4.9.1 Introduction
4.9.2 Revenue and Forecasts
4.9.3 Annual Cost of Therapy
4.9.4 Treatment Usage Patterns
4.9.5 Geographical Segmentation
4.9.6 Drivers and Restraints for the Opioids Market for Post-operative Pain
4.9.7 Drivers
4.9.8 Restraints
4.10 Opioids Market for Other Indications
4.10.1 Introduction
4.10.2 Revenue
5 Opioids Market: Geographical Landscape
5.1 The US
5.1.1 Revenue and Forecasts
5.1.2 Annual Cost of Therapy
5.1.3 Treatment Usage Patterns
5.2 Top Five Countries in Europe
5.2.1 Revenue and Forecasts
5.2.2 Annual Cost of Therapy
5.2.3 Treatment Usage Patterns
5.3 Japan
5.3.1 Revenue and Forecasts
5.3.2 Annual Cost of Therapy
5.3.3 Treatment Usage Patterns
6 Opioids Market: Pipeline Analysis
6.1 Introduction
6.1.1 Research and Development Pipeline - Neuropathic Pain
6.1.2 Research and Development Pipeline - Cancer Pain
6.2 Profiles of Key Late-Stage Drugs in the Opioids Market
6.2.1 Fentanyl TAIFUN - AKELA Pharma Inc.
6.2.2 Fentanyl Sublingual Spray - INSYS Therapeutics, Inc.
6.2.3 Oxycodone hydrochloride - Mundipharma International Limited
6.2.4 CEP-33237 - Teva Pharmaceuticals (Cephalon, Inc.)
6.2.5 ELI-216 - Elite Pharmaceuticals, Inc.
7 Opioids Market: Competitive Landscape
7.1 Competitive Profiling
7.1.1 Pfizer, Inc. (King Pharmaceuticals)
7.1.2 Johnson & Johnson
7.1.3 Orexo AB
7.1.4 Endo Pharmaceuticals
7.1.5 Teva Pharmaceuticals (Cephalon, Inc.)
7.1.6 Purdue Pharma
7.1.7 Mundipharma
8 Opioids Market: Strategic Consolidations
8.1 Overview
8.1.1 M&A Deals by Indication
8.1.2 M&A Deals by Geography
8.1.3 M&A Deals by Value ($)
8.2 R&D Licensing Agreements
8.2.1 Deals by Indication
8.2.2 Deals by Geography
8.2.3 Deals by Phase
8.2.4 Deals by Value ($)
8.2.5 Deals by Type
8.3 Co-development Deals
9 Opioids Market: Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources
1.1 List of Tables
Table 1: Opioids Market, Global, Revenue ($bn), 2002-2010
Table 2: Opioids Market, Global Revenue ($bn), 2010-2017
Table 3: Global Revenue of Top Selling Opioids ($’000), 2007-2009
Table 4: Major Marketed Opioid Drugs
Table 5: Opioids Market, Global, Annual Cost of Therapy ($), 2002-2010
Table 6: Opioids Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 7: Opioids Market, Global Treatment Usage Patterns (million), 2002-2010
Table 8: Opioids Market, Global Treatment Usage Patterns (million), 2010-2017
Table 9: Opioids Market, Fibromyalgia Global Revenue ($m), 2002-2010
Table 10: Opioids Market, Fibromyalgia Global Revenue ($m), 2010-2017
Table 11: Opioids Market, Fibromyalgia Global Annual Cost of Therapy ($), 2002-2010
Table 12: Opioids Market, Fibromyalgia Global Annual Cost of Therapy ($), 2010-2017
Table 13: Opioids Market, Fibromyalgia Global Treatment Usage Patterns (million), 2002-2010
Table 14: Opioids Market, Fibromyalgia Global Treatment Usage Patterns (million), 2010-2017
Table 15: Opioids Market, Fibromyalgia Global Market Geographical Segmentation ($m), 2002-2010
Table 16: Opioids Market, Fibromyalgia Global Market Geographical Segmentation ($m), 2010-2017
Table 17: Opioids Market, Global, Neuropathic Pain Revenue ($m), 2002-2010
Table 18: Opioids Market, Global, Neuropathic Pain Revenue ($m), 2010-2017
Table 19: Opioids Market, Global, Neuropathic Pain Annual Cost of Therapy ($), 2002-2010
Table 20: Opioids Market, Global, Neuropathic Pain Annual Cost of Therapy ($), 2010-2017
Table 21: Opioids Market, Global, Neuropathic Pain Treatment Usage Patterns (million), 2002-2010
Table 22: Opioids Market, Global, Neuropathic Pain Treatment Usage Patterns (million), 2010-2017
Table 23: Opioids Market, Global, Neuropathic Pain Market Geographical Segmentation ($m), 2002-2010
Table 24: Opioids Market, Global, Neuropathic Pain Market Geographical Segmentation ($m), 2010-2017
Table 25: Opioids Market, Global, Cancer Pain Revenue ($m), 2002-2010
Table 26: Opioids Market, Global, Cancer Pain Revenue ($m), 2010-2017
Table 27: Opioids Market, Global, Cancer Pain Annual Cost of Therapy ($), 2002-2010
Table 28: Opioids Market, Global, Cancer Pain Annual Cost of Therapy ($), 2010-2017
Table 29: Opioids Market, Global, Cancer Pain Treatment Usage Patterns (million), 2002-2010
Table 30: Opioids Market, Global, Cancer Pain Treatment Usage Patterns (million), 2010-2017
Table 31: Opioids Market, Global, Cancer Pain Market Geographical Segmentation ($m), 2002-2010
Table 32: Opioids Market, Global, Cancer Pain Market Geographical Segmentation ($m), 2010-2017
Table 33: Opioids Market, Osteoarthritis Pain Global Revenue ($bn), 2002-2010
Table 34: Opioids Market, Osteoarthritis Pain Global Revenue ($bn), 2010-2017
Table 35: Opioids Market, Osteoarthritis Pain Global Annual Cost of Therapy ($), 2002-2010
Table 36: Opioids Market, Osteoarthritis Pain Global Annual Cost of Therapy ($), 2010-2017
Table 37: Opioids Market, Osteoarthritis Pain Global Treatment Usage Patterns (million), 2002-2010
Table 38: Opioids Market, Osteoarthritis Pain Global Treatment Usage Patterns (million), 2010-2017
Table 39: Opioids Market, Osteoarthritis Pain Global Market Geographical Segmentation ($m), 2002-2010
Table 40: Opioids Market, Osteoarthritis Pain Global Market Geographical Segmentation ($m), 2010-2017
Table 41: Opioids Market, Rheumatoid Arthritis Pain Global Revenue ($m), 2002-2010
Table 42: Opioids Market, Rheumatoid Arthritis Global Revenue ($m), 2010-2017
Table 43: Opioids Market, Rheumatoid Arthritis Pain Global Annual Cost of Therapy ($), 2002-2010
Table 44: Opioids Market, Rheumatoid Arthritis Pain Global Annual Cost of Therapy ($), 2010-2017
Table 45: Opioids Market, Rheumatoid Arthritis Pain Global Treatment Usage Patterns (‘000), 2002-2010
Table 46: Opioids Market, Rheumatoid Arthritis Pain Global Treatment Usage Patterns (‘000), 2010-2017
Table 47: Opioids Market, Rheumatoid Arthritis Pain Global Market Geographical Segmentation ($m), 2002-2010
Table 48: Opioids Market, Rheumatoid Arthritis Pain Global Market Geographical Segmentation ($m), 2010-2017
Table 49: Opioids Market, Low Back Pain Global Revenue ($m), 2002-2010
Table 50: Opioids Market, Low Back Pain Global Revenue ($m), 2010-2017
Table 51: Opioids Market, Low Back Pain Global Annual Cost of Therapy ($), 2002-2010
Table 52: Opioids Market, Low Back Pain Global Annual Cost of Therapy ($), 2010-2017
Table 53: Opioids Market, Low Back Pain Global Treatment Usage Patterns (million), 2002-2017
Table 54: Opioids Market, Low Back Pain Global Treatment Usage Patterns (million), 2010-2017
Table 55: Opioids Market, Low Back Pain Global Market Geographical Segmentation ($m), 2002-2010
Table 56: Opioids Market, Global, Low Back Pain Market Geographical Segmentation ($m), 2010-2017
Table 57: Opioids Market, Post Operative Pain Global Revenue ($bn), 2002-2010
Table 58: Opioids Market, Global, Post Operative Pain Revenue ($bn), 2010-2017
Table 59: Opioids Market, Post Operative Pain Global Annual Cost of Therapy ($), 2002-2010
Table 60: Opioids Market, Post Operative Pain Global Annual Cost of Therapy ($), 2010-2017
Table 61: Opioids Market, Post Operative Pain Global Treatment Usage Patterns (million), 2002-2010
Table 62: Opioids Market, Post Operative Pain Global Treatment Usage Patterns (million), 2010-2017
Table 63: Opioids Market, Post Operative Pain Global Market Geographical Segmentation ($m), 2002-2010
Table 64: Opioids Market, Global, Post Operative Pain Market Geographical Segmentation ($m), 2010-2017
Table 65: Opioids Market, Others Global Revenue ($m), 2002-2010
Table 66: Opioids Market, Others Global Revenue ($m), 2010-2017
Table 67: Opioids Market, Global, Revenues by Geography ($bn), 2002-2010
Table 68: Opioids Market, Global, Revenues by Geography ($bn), 2010-2017
Table 69: Opioids Market, The US, Revenues ($bn), 2002-2010
Table 70: Opioids Market, The US, Revenues ($bn), 2010-2017
Table 71: Opioids Market, The US, Annual Cost of Therapy ($), 2002-2010
Table 72: Opioids Market, The US, Annual Cost of Therapy ($), 2010-2017
Table 73: Opioids Market, The US, Treatment Usage Pattern (million), 2002-2010
Table 74: Opioids Market, The US, Treatment Usage Pattern (million), 2010-2017
Table 75: Opioids Market, Top Five Countries in Europe, Revenues ($bn), 2002-2010
Table 76: Opioids Market, Top Five Countries in Europe, Revenues ($bn), 2010-2017
Table 77: Opioids Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010
Table 78: Opioids Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017
Table 79: Opioids Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2002-2010
Table 80: Opioids Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2010-2017
Table 81: Opioids Market, Japan, Revenues ($bn), 2002-2010
Table 82: Opioids Market, Japan, Revenues ($bn), 2010-2017
Table 83: Opioids Market, Japan Annual Cost of Therapy, ($), 2002-2010
Table 84: Opioids Market, Japan Annual Cost of Therapy, ($), 2010-2017
Table 85: Opioids Market, Japan, Treatment Usage Pattern (million), 2002-2010
Table 86: Opioids Market, Japan, Treatment Usage Pattern (million), 2010-2017
Table 87: Opioids Market, Global Major M&A Deals, 2009-2011
Table 88: Opioids Market, Global Major Co-developments Deals , 2009-2010
1.2 List of Figures
Figure 1: Opioids - A Classification
Figure 2: Opioids - Adverse Effects
Figure 3: Risk Evaluation and Mitigation Strategy, Components of REMS
Figure 4: Risk Evaluation and Mitigation Strategy, Implications for Patients
Figure 5: Risk Evaluation and Mitigation Strategy, Number of ED Visits Due To Drug Abuse in the US, 2004 and 2008
Figure 6: Opioids Market, Global, Revenue ($bn), 2002-2017
Figure 7: Global Revenue of Top Selling Opioids,($’000), 2007-2009
Figure 8: Opioids Market, Global, Annual Cost of Therapy ($), 2002-2017
Figure 9: Opioids Market, Global Therapeutic Usage Patterns, 2002-2017
Figure 10: Opioids Market, Global Diseased Population (million), 2002-2017
Figure 11: Opioids Market, Global Treatment Seeking Population (million), 2002-2017
Figure 12: Opioids Market, Global Diagnosed Population (million), 2002-2017
Figure 13: Opioids Market, Global Prescription Population (million), 2002-2017
Figure 14: Opioids Market, Drivers and Restraints, 2010
Figure 15: Opioids Market, Fibromyalgia, Global Revenue ($m), 2002-2017
Figure 16: Opioids Market, Fibromyalgia Global Annual Cost of Therapy ($), 2002-2017
Figure 17: Opioids Market, Fibromyalgia Global Treatment Usage Pattern (million), 2002-2017
Figure 18: Opioids Market, Fibromyalgia Global Diseased Population (million), 2002-2017
Figure 19: Opioids Market, Fibromyalgia Global Treatment Seeking Population (million), 2002-2017
Figure 20: Opioids Market, Fibromyalgia Global Diagnosis Population (million), 2002-2017
Figure 21: Opioids Market, Fibromyalgia Global Prescription Population (million), 2002-2017
Figure 22: Opioids Market, Fibromyalgia Global Market Segmentation by Geography (%), 2010 and 2017
Figure 23: Opioids Market, Fibromyalgia Global Market Geographical Segmentation ($m), 2002-2017
Figure 24: Opioids Market, Fibromyalgia Drivers and Restraints, 2010
Figure 25: Opioids Market, Global, Neuropathic Pain Revenue ($m), 2002-2017
Figure 26: Opioids Market, Global, Neuropathic Pain Annual Cost of Therapy ($), 2002-2017
Figure 27: Opioids Market, Global, Neuropathic Pain Treatment Usage Patterns (million), 2002-2017
Figure 28: Opioids Market, Global, Neuropathic Pain Diseased Population (million), 2002-2017
Figure 29: Opioids Market, Global, Neuropathic Pain Treatment Seeking Population (million), 2002-2017
Figure 30: Opioids Market, Global, Neuropathic Pain Diagnosis Population (million), 2002-2017
Figure 31: Opioids Market, Global, Neuropathic Pain Prescription Population (million), 2002-2017
Figure 32: Opioids Market, Global, Neuropathic Pain Market Segmentation by Geography, 2010 and 2017
Figure 33: Opioids Market, Global, Neuropathic Pain Market Geographical Segmentation ($m), 2002-2017
Figure 34: Opioids Market, Neuropathic Pain Global Drivers and Restraints, 2010
Figure 35: Opioids Market, Global, Cancer Pain Revenue ($bn), 2002-2017
Figure 36: Opioids Market, Global, Cancer Pain Annual Cost of Therapy ($), 2002-2017
Figure 37: Opioids Market, Global, Cancer Pain Treatment Usage Patterns (million), 2002-2017
Figure 38: Opioids Market, Global, Cancer Pain Diseased Population (million), 2002-2017
Figure 39: Opioids Market, Global, Cancer Pain Treatment Seeking Population (million), 2002-2017
Figure 40: Opioids Market, Global, Cancer Pain Diagnosis Population (million), 2002-2017
Figure 41: Opioids Market, Global, Cancer Pain Opioid Prescription Population (million), 2002-2017
Figure 42: Opioids Market, Global, Cancer Pain Market Segmentation by Geography, 2010 and 2017
Figure 43: Opioids Market, Global, Cancer Pain Market Geographical Segmentation ($m), 2002-2017
Figure 44: Opioids Market, Cancer Pain Drivers and Restraints, 2010
Figure 45: Opioids Market, Osteoarthritis Pain Global Revenue ($bn), 2002-2017
Figure 46: Opioids Market, Osteoarthritis Pain Global Annual Cost of Therapy ($), 2002-2017
Figure 47: Opioids Market, Osteoarthritis Pain Global Treatment Usage Patterns (million), 2002-2017
Figure 48: Opioids Market, Osteoarthritis Pain Global Diseased Population (million), 2002-2017
Figure 49: Opioids Market, Osteoarthritis Pain Global Treatment Seeking Population (million), 2002-2017
Figure 50: Opioids Market, Osteoarthritis Pain Global Diagnosis Population (million), 2002-2017
Figure 51: Opioids Market, Osteoarthritis Pain Global Prescription Population (million), 2002-2017
Figure 52: Opioids Market, Osteoarthritis Pain Global Market Segmentation by Geography (%), 2010 and 2017
Figure 53: Opioids Market, Global, Osteoarthritis Pain Market Geographical Segmentation ($m), 2002-2017
Figure 54: Opioids Market, Osteoarthritis Pain Drivers and Restraints, 2010
Figure 55: Opioids Market, Rheumatoid Arthritis Pain Global Revenue ($m), 2002-2017
Figure 56: Opioids Market, Rheumatoid Arthritis Pain Global Annual Cost of Therapy ($), 2002-2017
Figure 57: Opioids Market, Rheumatoid Arthritis Pain Global Treatment Usage Patterns (million), 2002-2017
Figure 58: Opioids Market, Rheumatoid Arthritis Pain Global Diseased Population (million), 2002-2017
Figure 59: Opioids Market, Rheumatoid Arthritis Pain Global Treatment Seeking Population (million), 2002-2017
Figure 60: Opioids Market, Rheumatoid Arthritis Pain Global Diagnosis Population (million), 2002-2017
Figure 61: Opioids Market, Rheumatoid Arthritis Pain Global Prescription Population (million), 2002-2017
Figure 62: Opioids Market, Rheumatoid Arthritis Pain Global Market Segmentation by Geography (%), 2010 and 2017
Figure 63: Opioids Market, Rheumatoid Arthritis Pain Global Market Geographical Segmentation ($m), 2002-2017
Figure 64: Opioids Market, Rheumatoid Arthritis Pain Drivers and Restraints, 2010
Figure 65: Opioids Market, Low Back Pain Global Revenue ($m), 2002-2017
Figure 66: Opioids Market, Low Back Pain Global Annual Cost of Therapy ($), 2002-2017
Figure 67: Opioids Market, Low Back Pain Global Treatment Usage Patterns (million), 2002-2017
Figure 68: Opioids Market, Low Back Pain Global Diseased Population (million), 2002-2017
Figure 69: Opioids Market, Low Back Pain Global Treatment Seeking Population (million), 2002-2017
Figure 70: Opioids Market, Low Back Pain Global Diagnosis Population (million), 2002-2017
Figure 71: Opioids Market, Low Back Pain Global Prescription Population (million), 2002-2017
Figure 72: Opioids Market, Low Back Pain Global Market Segmentation by Geography (%), 2010 and 2017
Figure 73: Opioids Market, Low Back Pain Global Market Geographical Segmentation ($m), 2002-2017
Figure 74: Opioids Market, Low Back Pain Drivers and Restraints, 2010
Figure 75: Opioids Market, Global, Post Operative Pain Revenue ($bn), 2002-2017
Figure 76: Opioids Market, Post Operative Pain Global Annual Cost of Therapy ($), 2002-2017
Figure 77: Opioids Market, Post Operative Pain Global Treatment Usage Patterns (million), 2002-2017
Figure 78: Opioids Market, Post Operative Pain Global Diseased Population (million), 2002-2017
Figure 79: Opioids Market, Post Operative Pain Global Treatment Seeking Population (million), 2002-2017
Figure 80: Opioids Market, Post Operative Pain Global Diagnosis Population (million), 2002-2017
Figure 81: Opioids Market, Post Operative Pain Global Prescription Population (million), 2002-2017
Figure 82: Opioids Market, Post Operative Pain Global Market Segmentation by Geography (%), 2010 and 2017
Figure 83: Opioids Market, Post Operative Pain Global Market Geographical Segmentation ($m), 2002-2017
Figure 84: Opioids Market, Post Operative Pain Drivers and Restraints, 2010
Figure 85: Opioids Market, Others Global Revenue ($m), 2002-2017
Figure 86: Opioids Market, Global, Market Share by Geography (%), 2010 and 2017
Figure 87: Opioids Market, Global, Revenues by Geography ($bn), 2002-2017
Figure 88: Opioids Market, The US, Revenues ($bn), 2002-2017
Figure 89: Opioids Market, The US, Annual Cost of Therapy ($), 2002-2017
Figure 90: Opioids Market, The US, Treatment Usage Pattern (million), 2002-2017
Figure 91: Opioids Market, The US, Diseased Population (million), 2002-2017
Figure 92: Opioids Market, The US, Treatment Seeking Population (million), 2002-2017
Figure 93: Opioids Market, The US, Diagnosed Population (million), 2002-2017
Figure 94: Opioids Market, The US, Prescription Population (million), 2002-2017
Figure 95: Opioids Market, Top Five Countries in Europe, Revenues ($bn), 2002-2017
Figure 96: Opioids Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017
Figure 97: Opioids Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2002-2017
Figure 98: Opioids Market, Top Five Countries in Europe, Diseased Population (million), 2002-2017
Figure 99: Opioids Market, Top Five Countries in Europe, Treatment Seeking Population (million), 2002-2017
Figure 100: Opioids Market, Top Five Countries in Europe, Diagnosed Population (million), 2002-2017
Figure 101: Opioids Market, Top Five Countries in Europe, Prescription Population (million), 2002-2017
Figure 102: Opioids Market, Japan, Revenues ($bn), 2002-2017
Figure 103: Opioids Market, Japan, Annual Cost of Therapy ($), 2002-2017
Figure 104: Opioids Market, Japan, Treatment Usage Pattern (million), 2002-2017
Figure 105: Opioids Market, Japan, Diseased Population (million), 2002-2017
Figure 106: Opioids Market, Japan, Treatment Seeking Population (million), 2002-2017
Figure 107: Opioids Market, Japan, Diagnosis Population (million), 2002-2017
Figure 108: Opioids Market, Japan, Prescription Population (million), 2002-2017
Figure 109: Opioids Market, Global, R&D Pipeline by Indication (%), March 2010
Figure 110: Opioids Market, Global, R&D Pipeline by Phase (%), March 2010
Figure 111: Opioids Market, Global, Neuropathic Pain R&D Pipeline by Phase (%), 2010
Figure 112: Opioids Market, Global, Cancer Pain R&D Pipeline by Phase (%), 2010
Figure 113: Opioids Market, Global, SWOT - Pfizer, 2010
Figure 114: Opioids Market, Global, SWOT - Johnson & Johnson, 2010
Figure 115: Opioids Market, Global, SWOT - Orexo, 2010
Figure 116: Opioids Market, Global, SWOT - Endo Pharmaceuticals, 2010
Figure 117: Opioids Market, Global, SWOT - Cephalon, 2010
Figure 118: Opioids Market, Global, SWOT - Purdue Pharma, 2010
Figure 119: Opioids Market, Global, SWOT - Mundipharma, 2010
Figure 120: Opioids Market, Global, M&A Deals by Indication (%), 2005-2010
Figure 121: Opioids Market, Global, M&A Deals by Geography (%), 2005-2010
Figure 122: Opioids Market, Global, M&A Deals by Value (%), 2005-2010
Figure 123: Opioids Market, Global, Major Licensing Agreements by Indication (%), 2009-2010
Figure 124: Opioids Market, Global, Major Licensing Agreements by Geography (%), 2009-2010
Figure 125: Opioids Market, Global, Major Licensing Agreements by Phase (%), 2009-2010
Figure 126: Opioids Market, Global, Major Licensing Agreements by Value (%), 2009-2010
Figure 127: Opioids Market, Global, Major Licensing Agreements by Type (%), 2009-2010
Figure 128: Opioids Market, Global, Co-Development Deals By Indication (%), 2009-2010
Figure 129: Opioids Market, Global, Co-Development Deals By Geography (%), 2009-2010
Figure 130: GBI Research Market Forecasting Model

Abstract

Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market”, which provides insights into global opioids market and market forecast until 2017. The report provides an in-depth analysis of the top seven therapeutic indications for which often opioids are prescribed which includes fibromyalgia, neuropathic pain, cancer pain, osteoarthritis pain, rheumatoid arthritis pain, low back pain and post operative pain. The report also examines the global opioids treatment usage patterns for the covered indication. In addition, the report also includes insights into the opioids R&D pipeline.

Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research analysis shows that the overall global opioids market for the seven indications fibromyalgia, neuropathic pain, cancer pain, osteoarthritis pain, rheumatoid arthritis pain, low back pain and post operative pain was valued at $11.2 billion in 2010. The market is expected to witness a CAGR of 2.8% for the forecast period. Patent expiries of leading opioids followed by generic erosions along with adverse effects associated with use of opioids are the main reasons for marginal growth in opioids market. However expected launch of new opioids is expected to push the market in future.

The US was the largest region for the opioids market in terms of revenue, accounting for 49% followed by top five countries in Europe and Japan which contributed 36% and 15% respectively.

The top pharmaceutical companies in opioids market are - Johnson & Johnson, Cephalon and several mid size players such as Purdue Pharma, King Pharmaceuticals, Orexo and Endo Pharmaceuticals. Large amount of fragmentation in the market provides significant scope for consolidation through mergers and acquisitions.

Scope

The scope of this report includes -
  • Data and analysis on the global opioids market.
  • Annualized market data for the opioids market from 2002 to 2010, with forecasts to 2017.
  • Market data on the therapeutic landscape which covers fibromyalgia, neuropathic pain, cancer pain, osteoarthritis pain, rheumatoid arthritis pain, low back pain and post operative pain therapeutics including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.
  • Key drivers and restraints that have had a significant impact on the market and on each indication.
  • The competitive landscape of the global opioids market which includes companies such as Johnson & Johnson, Cephalon, Purdue Pharma, King Pharmaceuticals, Orexo and Endo Pharmaceuticals.
  • Key M&A activities and Licensing Agreements that took place from 2005 to 2010 in the global opioids market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to -
  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
  • Device a more tailored country strategy through the understanding of key drivers and barriers of the region’s opioids market.
  • Develop key strategic initiatives by understanding the key focus areas and top selling opioids molecules of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.